Category Archives: Receptor Tyrosine Kinase Inhibitors

Saliva Test to Detect EGFR Mutations and Guide Therapy in Lung Cancer

A new technology called electric field–induced release and measurement (EFIRM) is able to detect biomarkers in saliva for non-small cell lung cancer (NSCLC). The test detects circulating tumor DNA (ctDNA). It is able to detect actionable EGFR (epidermal growth factor receptor) mutations in NSCLC patients with 100% concordance with biopsy-based genotyping, Dr Wong (study author) said, and it can detect the most common EGFR gene mutations that are treatable with TKIs (tyrosine kinase inhibitors), such as gefitinib (Iressa, AstraZeneca Pharmaceuticals LP) or erlotinib (Tarceva, Genentech/Roche). Continue reading

Three Recent Late Stage Disappointments for Lung Cancer, Pancreatic Cancer, Sarcoma, and Glioblastoma

In the last several months, three novel drugs that we have been following on this blog failed in late stage clinical trials. The drugs have diverse mechanisms of action:

3 drugsv2

Continue reading

Oncodesign and Bristol Myers Squibb Enter Collaboration for Novel Kinase Inhibitors

Bristol-Myers Squibb recruited French biotech Oncodesign to help it find new ways of attacking tumors, signing an early-stage agreement in hopes of spotlighting some promising projects. Continue reading

Priority Review for Potent Novel Therapy for Chronic Lymphocytic Leukemia (CLL)

Venetoclax is a novel cancer therapy being developed by Roche and AbbVie. The U.S. FDA has accepted the New Drug Application and granted Priority Review and Breakthrough Therapy Designation for venetoclax for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion. Continue reading

Argos’ Metastatic Renal Cell Carcinoma Study Passes Independent Data Safety Monitoring Committee Second Interim Analysis

An independent data monitoring committee (IDMC) has recommended the continuation of Argos’ pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee’s second planned interim data analysis. The next planned interim analysis will be in 6 months. Continue reading

Exploiting the Tumor Microenvironment – Threshold, Bioatla, Pfizer

Two companies announced news last week regarding their efforts to treat cancer by administering treatments that become activated by physiological conditions specific to the tumor microenvironment. Threshold Pharmaceuticals announced data from Phase III clinical trials of evophosphamide (TH-302), and BioAtla announced an antibody development deal with Pfizer. Continue reading

Gilteritinib in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. This type of cancer usually gets worse quickly if it is not treated. Continue reading

Liquid Biopsy from Pathway Genomics – Appropriate Uses

Liquid biopsy is the use of blood to diagnose cancer. Pathway Genomics launched its CancerIntercept test that screens for multiple cancers. Continue reading

Entinostat Doesn’t Just Restore Sensitivity to Aromatase Inhibitors

Entinostat is currently in a Phase III trial in combination with Aromasin (exemestane – aromatase inhibitor that blocks the synthesis of estrogen) in patients with metastatic breast cancer who have recurred following treatment with an aromatase inhibitor. Continue reading

New Epidermal Growth Factor Strategies in the Clinic for Glioblastoma & Lung Cancer

Two companies, Celldex and Clovis, reported positive developments with their strategies to target the mutated Epidermal Growth Factor Receptor for patients with glioblastoma and lung cancer. Continue reading